Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia.
Rearrangements of JAK2 are rare and have been described in various hematological neoplasms. We report a novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in a 14-year-old male with a diagnosis of B lymphoblastic leukemia. He was treated with Children's Oncology Group's protocol (AALL0232) but failed to achieve remission by day 29. He underwent a second induction and entered remission. His clinical course suggested that this JAK2 rearrangement might portend an unfavorable prognosis. This case brings the total number of JAK2 rearranged lymphoblastic leukemia cases in the literature to seven. The molecular genetic and clinicopathologic features of these cases were reviewed.
Tirado
Carlos A
CA
Department of Pathology, Clinical Cytogenetics, The University of Texas, Southwestern Medical Center at Dallas, Dallas, TX 75390-9073, USA. carlos1.tirado@utsouthwestern.edu
Chen
Weina
W
Huang
Lily Jun-shen
LJ
Laborde
Carrie
C
Hiemenz
Matthew C
MC
Valdez
Federico
F
Ho
Kevin
K
Winick
Naomi
N
Lou
Zhenjun
Z
Koduru
Prasad
P
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002892:Chromosomes, Human, Pair 22 / Q000235:genetics*; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics*; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D015448:Leukemia, B-Cell / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics*; D014178:Translocation, Genetic
C507924:JAK2 protein, human; D053614:Janus Kinase 2